» Articles » PMID: 26846300

SOX2 Suppresses CDKN1A to Sustain Growth of Lung Squamous Cell Carcinoma

Overview
Journal Sci Rep
Specialty Science
Date 2016 Feb 6
PMID 26846300
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Since the SOX2 amplification was identified in lung squamous cell carcinoma (lung SCC), SOX2 transcriptional downstream targets have been actively investigated; however, such targets are often cell line specific. Here, in order to identify highly consensus SOX2 downstream genes in lung SCC cells, we used RNA-seq data from 178 lung SCC specimens (containing tumor and tumor-associated cells) and analyzed the correlation between SOX2 and previously-reported SOX2-controlled genes in lung SCC. In addition, we used another RNA-seq dataset from 105 non-small cell lung cancer cell lines (NSCLC; including 4 lung SCC cell lines) and again analyzed the correlation between SOX2 and the reported SOX2-controlled genes in the NSCLC cell lines (no tumor-associated cells). We combined the two analyses and identified genes commonly correlated with SOX2 in both datasets. Among the 99 genes reported as SOX2 downstream and/or correlated genes, we found 4 negatively-correlated (e.g., CDKN1A) and 11 positively-correlated genes with SOX2. We used biological studies to demonstrate that CDKN1A was suppressed by SOX2 in lung SCC cells. G1 cell cycle arrest induced by SOX2 siRNA was rescued by CDKN1A siRNA. These results indicate that the tumorigenic effect of SOX2 in lung SCC cells is mediated in part by suppression of CDKN1A.

Citing Articles

Transforming tumoroids derived from ALK-positive pulmonary adenocarcinoma to squamous cell carcinoma in vivo.

Yokota E, Iwai M, Ishida Y, Yukawa T, Matsubara M, Naomoto Y Hum Cell. 2024; 37(4):1132-1140.

PMID: 38829559 PMC: 11194197. DOI: 10.1007/s13577-024-01085-8.


USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity.

Kwon J, Zhang J, Mok B, Allsup S, Kim C, Toretsky J Mol Cancer. 2023; 22(1):204.

PMID: 38093367 PMC: 10717271. DOI: 10.1186/s12943-023-01892-x.


G1 Dynamics at the Crossroads of Pluripotency and Cancer.

Fleifel D, Cook J Cancers (Basel). 2023; 15(18).

PMID: 37760529 PMC: 10526231. DOI: 10.3390/cancers15184559.


Strategies for understanding the role of cellular heterogeneity in the pathogenesis of lung cancer: a cell model for chronic exposure to cigarette smoke extract.

Xia D, Liu J, Yong J, Li X, Ji W, Zhao Z BMC Pulm Med. 2022; 22(1):333.

PMID: 36056339 PMC: 9438261. DOI: 10.1186/s12890-022-02116-6.


Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and Therapies.

Zheng Y, Wang L, Yin L, Yao Z, Tong R, Xue J Front Oncol. 2022; 12:873994.

PMID: 35719973 PMC: 9204354. DOI: 10.3389/fonc.2022.873994.


References
1.
Maeda Y, Dave V, Whitsett J . Transcriptional control of lung morphogenesis. Physiol Rev. 2007; 87(1):219-44. DOI: 10.1152/physrev.00028.2006. View

2.
Maeda Y, Chen G, Xu Y, Haitchi H, Du L, Keiser A . Airway epithelial transcription factor NK2 homeobox 1 inhibits mucous cell metaplasia and Th2 inflammation. Am J Respir Crit Care Med. 2011; 184(4):421-9. PMC: 3175541. DOI: 10.1164/rccm.201101-0106OC. View

3.
Pikor L, Ramnarine V, Lam S, Lam W . Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013; 82(2):179-89. DOI: 10.1016/j.lungcan.2013.07.025. View

4.
Avilion A, Nicolis S, Pevny L, Perez L, Vivian N, Lovell-Badge R . Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 2003; 17(1):126-40. PMC: 195970. DOI: 10.1101/gad.224503. View

5.
Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C . Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21):3543-51. DOI: 10.1200/JCO.2007.15.0375. View